Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

ABSTRACT

KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations. Here, we describe ARS-853, a selective, covalent inhibitor of KRAS$^{G12C}$ that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation. Based on the rates of engagement and inhibition observed for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRAS$^{G12C}$ is in a state of dynamic flux that can be modulated by upstream signaling factors. These studies provide convincing evidence that the KRAS$^{G12C}$ mutation generates a “hyperexcitable” rather than a “statically active” state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.

SIGNIFICANCE: A cell-active, mutant-specific, covalent inhibitor of KRAS$^{G12C}$ is described that targets the GDP-bound, inactive state and prevents subsequent activation. Using this novel compound, we demonstrate that KRAS$^{G12C}$ oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state. Cancer Discov; 6(3): 316-29. © 2016 AACR.

See related commentary by Westover et al., p. 233.

INTRODUCTION

Cancer genome sequencing efforts over the past 10 to 15 years have led to the identification of numerous oncogenes responsible for the development and maintenance of human cancers. These discoveries stimulated widespread oncogene-targeted drug-development efforts leading to the approval of a number of novel and efficacious targeted therapies, particularly against targets in the protein kinase family. Notably absent from the growing list of oncogenes with corresponding targeted therapeutics is the first to be discovered, and the most prevalent oncogene in human cancers, RAS. Cancers harboring RAS mutations remain essentially untreatable more than 30 years after the initial discovery of the oncogene.

RAS was for many years considered to be undruggable, but several recent reports have generated renewed interest in the development of direct RAS inhibitors (1). Molecules binding directly to RAS and inhibiting interaction with its activator SOS (2, 3) or effector RAF (4) have been reported. A third published approach specifically and covalently targeted the G12C mutation of KRAS with either electrophilic GDP mimetics (5) or electrophilic compounds targeting a novel allosteric pocket under the Switch II loop region exposed exclusively in the GDP-bound state of KRAS (6). Compounds described in the latter work were found to inhibit RAS activity by blocking SOS-mediated nucleotide exchange and/or altering the relative affinity of KRAS for GDP versus GTP nucleotide. These innovative approaches demonstrated the presence of previously unknown binding pockets on the surface of RAS and provide a framework for continued efforts to develop novel RAS-targeted therapies.

Importantly, none of the recently presented KRAS-targeting approaches resulted in a compound with clearly demonstrated activity against mutant KRAS in cells. Here, we have focused on the novel Switch II pocket described by Ostrem and colleagues (6) and discovered a compound, ARS-853, with robust cellular activity against KRAS$^{G12C}$ in the low micromolar range. A detailed biochemical and cellular characterization of the mechanism of action of ARS-853 revealed an unexpected plasticity in the nucleotide/activity state of KRAS$^{G12C}$. As opposed to the classic view of mutant KRAS as a constitutively active enzyme, we have discovered that the KRAS$^{G12C}$ mutant rapidly cycles nucleotide and is thus responsive to upstream signaling inputs. These findings validate an unexpected strategy of targeting inactive mutant KRAS, and further provide a framework for exploring synergistic drug combinations and mechanisms of resistance to mutant KRAS inhibition.

RESULTS

Identification of Inhibitors That Selectively Engage KRAS$^{G12C}$ Oncoprotein in Cells

In order to further characterize the cellular activity of the previously reported inhibitors and to enable the development of improved KRAS$^{G12C}$ inhibitors with potent cellular activity, we developed an LC/MS-MS-based assay to directly and quantitatively determine engagement of KRAS$^{G12C}$ in a cellular setting (Fig. 1A). Briefly, the decrease of the cysteine 12 (C12)-containing peptide from tryptic digests of KRAS$^{G12C}$-mutant cells following compound treatment is quantified relative to isotopic standard peptides. Using this assay we found that Compound 12 (6) did not show substantial KRAS$^{G12C}$ covalent engagement in NCI-H358 (H358) cells, which harbor...
**Research Article**

Patricelli et al.

**Figure 1.** Identification of a covalent KRAS<sup>G12C</sup> inhibitor active in cells. 

A, schematic of the method for detecting small molecule engagement of KRAS<sup>G12C</sup> in cells by LC/MS-MS. Engagement is observed as a loss of the C12 containing tryptic peptide (KRAS<sup>G12C</sup> residues 6–16) relative to a control peptide (KRAS/NRAS residues 136–147). Each peptide is quantified relative to an internal standard (green and red, respectively) spiked in following the tryptic digest.

B, KRAS<sup>G12C</sup> signal intensity and LC/MS-MS extracted ion chromatograms of representative runs (upper right) from LC/MS-MS analyses of tryptic digests following 6-hour treatment of H358 cells (*, \(P < 0.05\); **, \(P < 0.01\)).

C, LC/MS-MS–extracted ion chromatogram showing adduct formation between the KRAS C12 tryptic peptide and ARS-107 in samples from B.

D, chemistry design scheme from Compound 12 to ARS-853.

E, KRAS<sup>G12C</sup> signal intensity and LC/MS-MS analyses of tryptic digests following treatment of H358 cells as indicated for 6 hours (#, \(P < 0.001\)).

B–E, error bars, mean ± SD (biologic replicates, \(n = 3\)).

F, crystal structure of ARS-853 bound to KRAS<sup>G12C</sup> highlighting key hydrogen bonds and hydrophobic interactions in the Switch II pocket.

G, deconvoluted electrospray mass spectra of 2 μmol/L KRAS<sup>G12C</sup> (average MW 21,485) treated with ARS-853 (MW 432) for indicated times. ARS-853 covalently engages GDP-loaded KRAS<sup>G12C</sup> in a time-dependent manner, but not GMPPNP-loaded active KRAS<sup>G12C</sup>.

H, EDTA-mediated nucleotide release assay with GDP-bound KRAS<sup>G12C</sup> protein prelabeled with the indicated inhibitor, and mant-GTP as excess incoming nucleotide.

I, SOS-mediated nucleotide exchange assay with GDP-bound KRAS<sup>G12C</sup> protein prelabeled with the indicated inhibitor, and mant-GTP as incoming nucleotide.
Targeting Inactive KRASG12C Suppresses Oncogenic Signaling

the KRASG12C mutation, even after a 6-hour treatment with 100 μmol/L compound (Fig. 1B).

To address the possible reasons for the lack of cellular efficacy observed for Compound 12, more potent Switch II pocket inhibitors were needed. With this aim, we performed iterative structure-based design of covalent KRASG12C-targeted agents and tested candidates for their activity against purified, recombinant KRASG12C, as well as their ability to engage KRASG12C in cells. An early strong biochemical hit, ARS-107, exhibited promising KRASG12C engagement in cells (Fig. 1B). Consistent with the loss of the C12 tryptic peptide of KRASG12C, we detected a dose-dependent increase in a peptide species matching the adduct of ARS-107 with the C12 tryptic peptide (Fig. 1C). Structural and iterative structure activity relationship (SAR) evaluation of ARS-107 and related compounds suggested that the S-chloro position on the phenyl ring was critical for activity; thus, this position was the focus of further optimization (Fig. 1D). Several compounds with improved biochemical activity and cellular activity were synthesized (Supplementary Table S1), leading to the most potent compound, ARS-853. ARS-853 engaged KRASG12C in the biochemical assay with a rate constant of 76 M−1 s−1, a more than 600-fold improvement compared with Compound 12, and a cellular engagement IC50 at 6 hours of 1.6 μmol/L (Fig. 1E; Supplementary Table S1).

The high-resolution crystal structure of ligand-bound KRASG12C in the presence of GDP confirmed the binding site of ARS-853 as the previously described Switch II pocket (Fig. 1F; Supplementary Fig. S1A–F; Supplementary Table S2). In the structure, ARS-853 is covalently attached to C12 and extends into the Switch II pocket region located between the central beta-sheet of KRAS and the α2 and α3 helices. Relative to other published structures of Switch II–bound compounds, ARS-853 induces a rotation of the α2 helix accompanied by a shift of M72 to accommodate the ligand in a distinct hydrophobic pocket. This hydrophobic pocket is occupied by the aromatic ring of ARS-853 with the chloro- and methycyclopropyl substituents providing tight van der Waals contacts, while the phenolic hydroxyl group makes a hydrogen bond with D69. The carbonyl group of the acrylamide warhead of ARS-853 makes hydrogen bonds to the conserved K16 and D69. The carbonyl of one of the water molecules coordinated to the customary magnesium ion while occupying a position similar to the terminal phosphate in the GTP-bound form of KRAS. In the bound structure, both Switch I and Switch II adopt ordered conformations distinct from their active forms, suggesting that binding to activator or effector proteins may be impaired. Overall, multiple features of the structure suggest that ARS-853–bound KRASG12C represents an inactive state of KRAS.

The structural evaluation of ARS-853 suggested several promising possible mechanisms for inhibition of KRAS function, including interference with GTP binding, stabilization of bound Mg2+/GDP, and/or blocking activator and/or effector binding in the Switch II region. These possibilities were directly explored in biochemical assays. Although ARS-853 reacted rapidly and selectively with GDP-bound KRASG12C, we were unable to detect reaction of ARS-853 with GTP-bound KRASG12C (Fig. 1G; Supplementary Table S3). This strong preference for reaction with GDP-bound KRASG12C is consistent with the positioning of C12-bound acrylamide carbonyl oxygen in the space typically occupied by the GTP γ-phosphate. Evaluation of the nucleotide exchange properties of KRASG12C bound to ARS-853 further confirmed the structural predictions. Following reaction with ARS-853, GDP-bound KRASG12C showed a dramatic decrease in EDTA-catalyzed nucleotide release in the presence of either GTP or GDP as excess incoming nucleotides (Fig. 1H; Supplementary Fig. S2A–D). The extent of this bound Mg2+/GDP stabilization effect correlated with compound engagement potency across a set of ARS-853–related compounds (Fig. 1H; Supplementary Fig. S2A–D), suggesting cooperative binding between the Mg2+/GDP and the covalent inhibitor. This effect may be correlated structurally with the indirect Mg2+ coordination observed in the crystal structure. ARS-853 and related analogues completely inhibited SOS catalyzed nucleotide exchange with either GDP or GTP as incoming nucleotide (Fig. II; Supplementary Fig. S2E–H), consistent with both Mg2+ stabilization and general interference with Switch II function. Together, these data suggest an inhibitory mechanism of action whereby ARS-853 reacts specifically with GDP-bound KRASG12C, and once bound prevents formation of the GTP-bound state through either intrinsic or catalyzed exchange mechanisms.

Before evaluating the effects of ARS-853 on cell functional readouts, we directly assessed its covalent selectivity across free cysteines in the proteome using an assay similar to that described by Wang and colleagues (ref. 7; Fig. 2A–B; Supplementary Fig. S3; Supplementary Table S4). Across the 2,740 surface-exposed cysteine residues profiled from 1,584 proteins, KRASG12C was the most potently engaged target observed. Only two other targets, FAM213A and Reticulon-4 (RTN4), displayed significant engagement at doses lower than 30 μmol/L. Importantly, these two off-targets were also observed in A549 cells, which harbor the G12S oncogene and were chosen as a control line for subsequent studies (Fig. 2C).

ARS-853 Inhibits KRASG12C Oncoprotein Function in Cells

We investigated the cellular effects of ARS-853 by monitoring the impact of treatment on active KRAS levels and RAS-mediated signaling in cells. ARS-853 treatment of KRASG12C cells led to a dose-dependent and nearly complete inhibition of CRAF-RBD (RBD)–mediated pulldown of KRAS from lysates, with an IC50 of approximately 1 μmol/L (Fig. 3A, left). The effect of ARS-853 treatment on the critical interaction of active KRAS with its effector protein CRAF in cells was determined by a proximity ligation assay (Fig. 3B). This method allows for the visualization of cellular KRAS–CRAF interactions through the proximity-dependent annealing and amplification of homologous DNA sequences present on antibodies to the two respective targets. Treatment of H358 cells by ARS-853 resulted in a significant loss of KRAS–CRAF interactions. Consistent with an inactive state of KRASG12C once bound to ARS-853, downstream signaling through both MAPK (including pMEK, pERK, and pRSK) and PI3K (pAKT) pathways was inhibited by ARS-853 in H358 and other KRASG12C cell lines (Fig. 3A; Supplementary Fig. S4A–C). The inhibition of RAF-RBD pulldown and KRAS downstream signaling was sustained over a period of 72 hours (Fig. 3C), accompanied by G1 cell-cycle arrest (Supplementary Fig. S4B), loss of Cyclin D1 and Rb expression, and an increase in the cell-cycle inhibitor p27 KIP1 (Fig. 3C; Supplementary Fig. S4A). In addition,
hallmarks of apoptosis, including cleaved PARP (Fig. 3A) and increases in sub-diploid DNA (Supplementary Fig. S4B), were observed in H358 cells following treatment with ARS-853. We observed no effects on RAF-RBD binding or downstream signaling in A549 cells (KRAS G12S , Fig. 3A, right), and the inhibitory effects of ARS-853 in H358 cells could be rescued by ectopic expression of KRAS G12V (Fig. 3D), highlighting the selectivity of ARS-853 for the KRAS G12C oncoprotein.

Consistent with its specific and complete ability to inhibit KRAS G12C signaling, ARS-853 selectively inhibited the growth of H358 cells in culture (Fig. 4A–D). Growth inhibition in H358 cells could be rescued by ectopic expression of KRAS G12V (Fig. 4A), and was observed for KRAS G12C, but not for KRAS G12V oncogenic transformation of NIH-3T3 fibroblasts (Supplementary Fig. S5) supporting the KRAS G12C oncoprotein–specific activity of ARS-853. In further support of an on-target mechanism of action, a small series of active and inactive structural analogues of ARS-853 inhibited the two-dimensional/adherent (2-D) proliferation of KRAS G12C-bearing H358 cells with a potency trend strongly correlating with biochemical and cellular target engagement (Supplementary Fig. S6; Supplementary Table S1).

Across a panel of cell lines, ARS-853 inhibited proliferation in 2-D growth assays in only a subset of the KRAS G12C lines tested (Fig. 4B, left). Despite the lack of growth inhibition in some lines, we found that ARS-853 effectively inhibited RAF-RBD
Targeting Inactive KRAS<sub>G12C</sub> Suppresses Oncogenic Signaling

KRAS knockdown by shRNA in a subset of these cells showed a similar trend of KRAS independence in an adherent growth format (Fig. 4E, Supplementary Fig. S7A–C), supporting that KRAS<sub>G12C</sub> lines not affected by ARS-853 in 2-D formats are generally not dependent on mutant KRAS for adherent growth. These findings are consistent with published studies showing that only a fraction of KRAS-mutated cell lines are dependent on the KRAS oncogene to support growth and survival in adherent/2-D assay formats (8–10).

KRAS dependence is well established to be more pronounced in 3-D and/or anchorage-independent settings than in adherent growth assays (10–12). In line with gene-targeted approaches (10–12), all tested KRAS<sup>G12C</sup> cell lines were robustly inhibited by ARS-853 in soft-agar colony formation assays with an average ∼2 μmol/L IC<sub>50</sub> (Fig. 4C and D). Using an alternative 3-D assay format consisting of identical assay conditions to the 2-D format, but using ultra-low adherent plates, allowed for a more direct comparison of adherent and nonadherent growth across a broad panel of cells. In this 3-D ultra-low adherent format, we observed robust inhibition of all 11 KRAS<sup>G12C</sup> cell lines tested (Fig. 4B, right). No inhibition of 13 non-KRAS<sup>G12C</sup> cell lines was observed in either adherent or anchorage-independent assay formats (Fig. 4B). Together, the molecular specificity of ARS-853, along with its selective inhibition of active KRAS<sub>G12C</sub>, downstream signaling, and KRAS<sub>G12C</sub> cell line growth, support that this compound is a selective and relatively potent KRAS<sub>G12C</sub> inhibitor.

ARS-853 Cellular Engagement Requires Rapid Cycling of Nucleotide on the KRAS<sub>G12C</sub> Oncoprotein

The structural and biochemical effects of ARS-853 described above support a mechanism of KRAS<sub>G12C</sub> inhibition that is
surprising given the expectation that mutant KRAS would be locked in a fully active state. ARS-853 showed exquisite selectivity for the GDP-bound form of KRAS-G12C (Fig. 1G; Supplementary Table S3) which would likely exist at low levels selectivity for the GDP-bound form of KRAS G12C (Fig. 1G; Supplementary Table S3) which would likely exist at low levels.

Figure 4. Cellular activity and selectivity of ARS-853. A, T-REx NCI-H358 cells stably expressing LacZ/TO or FLAG-KRAS-G12V/TO were cultured with doxycycline (10 ng/mL) 24 hours prior to treatment with indicated amounts of ARS-853. Effects on cell growth were monitored 5 days later by CellTiter- Glo.

B, the effects on adherent cell growth (left) or 3-D ultra-low adherent cell growth (right) following 5-day treatment with ARS-853. C, the effects on anchorage-independent growth in soft agar following 14-day treatment with ARS-853. Error bars, mean ± SD (across at least 2 independent experiments) or biologic duplicate wells (C), respectively. D, representative images of crystal violet–stained colony formation in soft agar displayed from Supplementary Fig. S7.

E, the effects of KRAS knockdown on ARS-853 treatment on growth in 2-D adherent or in 3-D soft-agar formats. Cells (20,000) stably transduced with lentivirus expressing shLuc or shKRAS were plated 48 hours following transduction in media containing 1 μg/mL puromycin in either 2-D adherent or 3-D soft-agar formats. Twenty-four hours following plating, cells were treated with or without ARS-853 (10 μmol/L). Growth was monitored after 10 to 14 days, and representative images of crystal violet–stained colony formation are depicted (see also Supplementary Fig. S5).

The cellular engagement kinetics for ARS-853 did not fit a typical/expected pseudo–first order curve, indicating the possibility that factors such as resting GDP-KRAS-G12C levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates. Importantly, engagement of the off-target RTN4 levels, and nucleotide cycling rates may be affecting engagement rates.
a good fit to the data, with half-lives for nucleotide release and hydrolysis of ~9.9 and 27 minutes respectively and a rate constant for ARS-853 engagement with GDP-KRAS of $1.17 \times 10^{-3}$ s$^{-1}$. The value determined for KRAS G12C nucleotide exchange rate in cells is significantly faster than the intrinsic exchange rates determined by us (Supplementary Table S5) and others (13, 14). A recent comparison of KRAS position 12 mutant properties, however, found that KRAS G12C hydrolyzed GTP with a half-life of 23 minutes (14), significantly faster than other mutants and consistent with our cellular characterization.

**KRAS G12C GTP Levels Are Modulated by Upstream Signaling Factors**

The faster-than-expected nucleotide cycling of KRAS G12C in cells prompted us to explore the intriguing possibility that mutant KRAS-GTP levels are regulated by the same signaling mechanisms that regulate wild-type (WT) RAS isoforms, such as growth factor receptor activation (Fig. 6A). Because H358 cells are heterozygous for KRAS G12C, we needed an assay capable of distinguishing the activation status of the KRAS G12C oncoprotein from the WT-KRAS isoform. To achieve this goal, we developed a mass spectrometry–based approach using the RAF-RBD as in the traditional active RAS pulldown assay, but incorporating a GMPPNP-bound, stable isotope-modified KRAS G12C (heavy KRAS G12C) protein as an internal reference. The heavy KRAS G12C standard is added to lysates immediately prior to the RAF-RBD capture step, and a quantitative LC/MS-MS analysis focused on the residue 12 containing tryptic peptide (to differentiate WT and G12C isoforms) is used to determine the active fraction of endogenous (light) KRAS G12C relative to the standard (RBD-MS assay; Supplementary Fig. S9A). By adding a GMPPNP-loaded heavy NRAS standard, we are also able to quantify the active fraction of the combined WT-RAS pool (Supplementary Fig. S9B). Following treatment with the EGFR inhibitor erlotinib, we observed a significant, time-dependent decrease in the KRAS G12C GTP fraction (Fig. 6B and C; Supplementary Fig. S10). Using the general kinetic model for KRAS nucleotide cycling described above (Fig. 5A), the best fit of the erlotinib-induced loss of active KRAS suggested a GTP hydrolysis half-life of 27 minutes, consistent with the kinetic modeling of ARS-853 engagement. Following...
Figure 6. Modulation of KRAS<sub>G12C</sub> activity alters ARS-853 target engagement and supports novel therapeutic strategies for targeting KRAS. A, schematic for altering KRAS-GTP through growth factor or small molecule inhibitors. B, RBD-MS analysis of H358 cells treated with erlotinib (2.5 μmol/L) harvested at the indicated time points. Experimental data values were used as input into the kinetic model parameters shown in Figure 4A (right). The fit estimates a GTP hydrolysis rate half-life on KRAS<sub>G12C</sub> of 27 minutes. C, RBD-MS analysis of GTP-bound KRAS<sub>G12C</sub> and WT-RAS (K/N/H isoforms) following pretreatment of H358 cells with EGF (100 ng/mL, 1 hour), erlotinib (2.5 μmol/L) 1 hour prior to ARS-853 addition, and EGF (100 ng/ml) was cotreated with ARS-853 and trametinib. *P < 0.001 by ANOVA compared with ARS-853 treatment alone. ARS-853 cell engagement is modulated consistent with specific reactivity to GDP-bound KRAS<sub>G12C</sub>. D, immunoblot experiment from biologic replicate lysates depicted in D. E, immunoblot experiment from biologic replicate lysates depicted in D. F, antiproliferative effects of ARS-853 treatment of H358 cells cultured with or without EGF (50 ng/mL) for 5 days. G, antiproliferative effects of combination treatments (0.4 μmol/L erlotinib, 0.1 μmol/L afatinib, or 50 nmol/L trametinib) on H358 cells cultured with or without EGF (50 ng/mL) for 5 days. H, immunoblot assessment KRAS signaling following 24 hours treatment of H358 cells with ARS-853 in combination with erlotinib (5 μmol/L), afatinib (100 nmol/L), or trametinib (100 nmol/L).
Targeting Inactive KRAS<sub>G12C</sub> Suppresses Oncogenic Signaling

The proposed model presents mutant KRAS<sub>G12C</sub> in a rapidly cycling state, whereby nucleotide exchange and hydrolysis occur and require signaling inputs (likely through exchange factors) to maintain high levels of the active, GTP-bound state. This model supports the following therapeutic opportunities as single agents or combinations: A, targeting the inactive-GDP bound state; B, targeting the active, GTP-bound state (an area of assumed focus as sole strategy); and C, targeting the RAS Guanine nucleotide exchange factor (GEF), or D alternative upstream inputs that regulate RAS-GEFs.

**Figure 7.** Schematic models of the conventional (left) and proposed model (right) for the maintenance and modulation of active mutant KRAS levels. The classic view of RAS activation, with KRAS<sub>G12C</sub> in the GDP-bound state, is shown in panel A, whereas panel B shows the proposed model with KRAS<sub>G12C</sub> in a rapidly cycling state. Panel C shows the proposed model with ARS-853 engagement and inhibiting MAPK signaling, accompanied by dramatic induction of apoptosis. Finally, panel D shows the proposed model with additional upstream inputs that regulate RAS-GEFs.

**DISCUSSION**

ARS-853 is the first direct KRAS inhibitor shown to selectively inhibit KRAS in cells with potency in the range of a drug candidate. Previously reported KRAS inhibitors have either shown insufficient potency for detailed cellular characterization (2, 3, 6), or exhibit dramatic deviations in potency across assays (4). The most potent covalent KRAS<sub>G12C</sub> ligand reported previously (Compound 12) exhibited promising in vitro properties, but its cellular effects were less clear (6). Here, we demonstrate that Compound 12 is not capable of engaging KRAS<sub>G12C</sub> in cells even at a relatively high dose and long incubation (100 μmol/L for 6 hours). However, by improving upon the groundbreaking approach of targeting the Switch II pocket of KRAS<sub>G12C</sub> with covalent ligands, we have successfully identified a covalent inhibitor that demonstrates consistent low micromolar activity from biochemical and cellular engagement to KRAS<sub>G12C</sub> activation, downstream signaling, and cell survival. Further, we have found that KRAS<sub>G12C</sub> is the most potent covalent target of ARS-853 across more than 2,700 cellular proteins and consistently find that this compound exerts no effects on cellular signaling or growth in non-KRAS<sub>G12C</sub> cells at concentrations up to 10-fold higher than its KRAS<sub>G12C</sub> potency. These studies clearly establish that ARS-853 is a selective and highly efficacious KRAS<sub>G12C</sub> inhibitor with low micromolar potency in cells.

Similar to the previously characterized Switch II pocket KRAS<sub>G12C</sub> inhibitor, ARS-853 reacts only with the inactive (GDP-bound), but not the active (GTP-bound), state of KRAS. Mutant RAS proteins have been shown to exist predominantly in the GTP-bound state (21–24) and the overall “cycle time” (change of nucleotide due to either exchange or hydrolysis) is...
ARS-853 binding to KRAS G12C leads to a generally inactive signaling and proliferation studies clearly demonstrate that bound state once bound by ARS-853. Although this precise on demonstrate that KRAS G12C is not locked in a fully activated state, but rather rapidly cycles its nucleotide state, allowing ARS-853 to achieve complete binding/inhibition over time as the oncprotein cycles its bound nucleotide (Fig. 7, right).

Based on the structural and biochemical effects of ARS-853, particularly the rapid inhibition of mutant KRAS signaling by ARS-853 will enable the interrogation of the connectivity and responsiveness of mutant KRAS signals prior to the induction or relief of compensating feedback mechanisms (19, 25). This will be invaluable for understanding the mechanisms underlying the reported variability of KRAS dependence across cell lines observed by us and others (8–10). From our initial studies of KRAS G12C-mediated signaling across cell lines (Supplementary Fig S4A) we have observed varying degrees of ARS-853 inhibition of downstream MAPK/PI3K signaling across the group of cell lines tested, suggesting that there are possible KRAS-independent mechanisms for maintenance of RAS signaling and that these inputs may contribute to differences in mutant KRAS dependence. Our studies with ARS-853 presented here have additionally confirmed that KRAS dependence is much more profound and universal in anchorage-independent settings. Future studies exploring the effects of ARS G12C inhibition on signaling in adherent and anchorage-independent settings may lead to a better mechanistic understanding of this feature of KRAS biology.

The observation that KRAS G12C activity levels are responsive to growth factor stimulation and inhibition supports further exploration of approaches targeting potential upstream KRAS inputs. The interaction of KRAS with its activator SOS (2, 3, 26–28), for example, may be a valid approach to suppress KRAS oncogenic signaling, at least in the setting of KRAS G12C-mutant tumors. Additionally, combination regimens of ARS G12C-targeted agents with inhibitors of targets upstream of KRAS may specifically enhance efficacy in KRAS G12C-harboring tumors. Importantly, although we have shown here that EGFR signaling can support active KRAS G12C levels, it is likely that the specific signaling inputs to KRAS will be cell type-specific. Thus, choosing the most effective combination agent may require an understanding of tumor-specific signaling vulnerabilities upstream of KRAS. Finally, the finding that KRAS G12C behaves in a manner distinct from expectations based on historic studies of more commonly explored RAS mutants (Q61K, G12V, G12D) suggests that general assumptions of mutant RAS properties should be directly explored across the spectrum of oncogenic RAS mutations. KRAS G12C may not be the only mutant RAS protein whose behavior deviates from the classic view of oncogenic RAS as a constitutively and fully active protein.

ARS-853 takes advantage of the unexpected nucleotide cycling features of KRAS G12C detailed above and represents the first direct KRAS inhibitor to achieve cellular potency in the range of a drug candidate. Further optimization will be required to generate compounds suitable for in vivo studies, but this work presents a significant step toward a direct KRAS inhibitor for the treatment of patients with the KRAS G12C mutation, which comprises 20% of lung cancers.

**METHODS**

**Cell Lines and Reagents**

Human cancer cell lines were purchased from the ATCC or the Korean Cell Line Bank (HCC-1171) and maintained at 37°C in a humidified atmosphere at 5% CO₂ and grown in RPMI 1640 or DMEM growth media (Gibco) supplemented with 10% fetal bovine serum (Gibco), 50 units/mL penicillin, and 50 μg/mL streptomycin (Gibco). NCI-H358, NCI-H23, A549, and A375 cell line identities were confirmed using the CellChek 16 (IDEXX Biosearch), an SNP-based profile authentication service, before studies were conducted. Cell lines utilized within the embodied work were purchased from ATCC (August 2014) and were carried for no longer than 12 cell passages. Erlotinib, afatinib, and trametinib were purchased from LC Laboratories. Recombinant human EGF was purchased from Life Technologies. All antibodies were purchased from Cell Signaling Technologies, except as follows: KRAS-specific antibody (clone C-19), NRAS-specific antibody (clone C-20), and HRAS-specific antibody (clone C-20) were from Santa Cruz Biotechnology; RAS-specific antibody (clone EPR3255) was from Abcam; and CRAF-specific antibody was from BD Biosciences.

**Protein Expression and Purification**

KRAS G12C, WT, and G13C proteins were expressed in *E. coli* as truncated (1-169), hexahistidine-tagged forms as described by Ostrem and colleagues (6). For crystallography studies, the KRAS G12C protein was expressed in *E. coli* and purified as described, including removal of the hexahistidine tag (6). Proteins used in biochemical studies were expressed and purified as described (6), except that the TEV cleavage (hexahistidine tag removal) and ion exchange chromatography steps were omitted. The resulting proteins were >95% pure as judged by SDS-PAGE. For SOS nucleotide exchange, the catalytic domain (594-1169) of SOS1 was expressed in *E. coli* and purified as described (6).

**Crystallization, Data Collection, and Refinement**

For X-ray crystallography, KRAS 1-169 (C55S/C80L/C118S) was used and the protein was prepared as described previously (6). Magnesium chloride (1 mmol/L final) and GDP (40 μmol/L final) were added to the freshly purified protein. After high-speed centrifugation, hanging drop crystallization conditions were set up by mixing 1:1 protein and reservoir solution (2.2 mol/L 3:2 NaH₂PO₄/K₂HPO₄, 0.2 mol/L Li₂SO₄, 0.1 mol/L glycine pH = 10.5). After several days at 20°C, thin plates were observed. The crystals were cryoprotected in the crystallization solution in a reservoir solution (2.2 mol/L 3:2 NaH₂PO₄/K₂HPO₄, 0.2 mol/L Li₂SO₄, 0.1 mol/L glycine pH = 10.5). After several days at 20°C, thin plates were observed. The crystals were cryoprotected in the crystallization solution
supplemented with 20% glycerol, flash-frozen, and stored in liquid nitrogen prior to obtaining diffraction data at beamline 5.0.1. (100 K nitrogen stream, wavelength = 0.9774 Å) at the Berkeley Lab Advanced Light Source. Data were initially processed with XMosfilm, solved by molecular replacement using Phaser and refined to the indicated statistics using Refmac (29). The refined model showed no Ramachandran outliers, and 98.5% of the residues were in the favored region (30).

**KRAS Biochemical Modification Assay**

GDP-loaded, hexahistidine-tagged, truncated (1-169) KRAS proteins (G12C, WT, G13D, as indicated) at 2 μmol/L final concentration were incubated with the test compounds at the doses and time points indicated in a buffer containing 20 mmol/L HEPES pH 7.5, 150 mmol/L NaCl, 1 mmol/L MgCl2, and 1 mmol/L DTT. Reactions were quenched by adding formic acid to 0.2%. The extent of covalent modification was determined by liquid chromatography, electrospray mass spectrometry analysis of the intact proteins on either a time of flight (TOF; Agilent 6530) or Q-Exactive (Thermo) mass spectrometer.

**Active RAS Determination by RBD Pulldown Assay**

Cells (2 × 10^6) preincubated for 15 min in a 10-cm dish (or 1 × 10^6 preincubated for 6-well plate per well) were treated with the indicated concentrations of compound for the time indicated. RAS activity was determined by the RAS activation kit from Cell Signaling Technology according to the manufacturer’s instructions. In brief, cells were lysed with 1 mL (or 0.5 mL) of lysis buffer containing 80 μg/mL of GST-tagged RBD for 10 minutes on ice. Cells were scrapped off and lysate was centrifuged at 14,000 rpm for 5 minutes at 4°C. Preincubated lysis samples were subsequently added to prewashed glutathione agarose beads for 1 hour at 4°C under constant rocking. The beads were subsequently pelleted and washed 3 times and eluted for Western blotting with 40 μL of 1x SDS-PAGE sample buffer. Immunodetection of RAS proteins was carried out with the following antibodies: KRAS (C-terminal specific) antibody (C-19; Santa Cruz Biotechnology; 1:250), NRAS (C-20; Santa Cruz Biotechnology; 1:250), H-RAS (C-20; Santa Cruz Biotechnology; 1:250), and pan-RAS antibody (EPR3255; Abcam; 1:4,000).

**RBD-MS Assay**

Samples were prepared as described for the RAS-GTP pulldown assay by Western blotting above with the following modifications. Immediately before cell lysis, 50 ng each of heavy isotopic labeled, GMPPNP-loaded KRAS-G12C and WT-NRAS protein standards were added to the lysis buffer. After lysis, 10% of the cell lysate was removed for precapture MS analysis, and the remaining 90% was precipitated with glutathione beads. The captured material was eluted with MS elution buffer (0.1% SDS, 10 mmol/L DTT). Both the RBD eluted samples and precapture lysate samples were acetone precipitated, resuspended in a buffer containing 9 mol/L urea, 10 mmol/L DTT, and 50 mmol/L ammonium bicarbonate, pH 8, and subjected to trypsin digest and MS analysis as described above for the G12C cell engagement assay. A detailed description of the calculations used to determine the RAS-GTP fraction can be found in Supplementary Methods.

**Lentivirus Generation and shRNA Constructs**

For mutant KRAS overexpression, codon-optimized cDNAs encoding N-terminal FLAG-tagged human KRAS (G12V and G12C) were cloned into pLenti6.2/V5-DEST gateway vector or the T-REx Gateway vector pLenti6.3/TO/VS-DEST (LifeTech). For inducible ectopic expression of KRAS or LacZ for rescue experiments, NCI-H358 cells were stably transduced with the tetracycline repressor–based backbone vector pLenti3.3/TR from the ViralPower HiPerform T-Rex Gateway vector kit as recommended by the manufacturer’s instructions (referred to as ‘T-Rex’ NCI-H358 cells) and were utilized for both signaling and proliferation analysis in Figs. 3D and 4A. MISSION shRNA TRC1.5 vector clones in the pLKO.1 puro backbone for KRAS and Luciferase were purchased from Sigma. The clone IDs for shRNAs are as follows: shKRAS #1 (TRCN0000032260), shKRAS #2 (TRCN0000032362), and shLuciferase (SHC007). Lentiviral particles were packaged in HEK293FT cells using the ViralPower Lentivector expression system (LifeTech) and transduced at a multiplicity of infection of 5 using standard recommended procedures. Cell cultures were spinfected in the presence of 5 to 8 μg/mL polybrene and centrifuged at 600 g for 30 minutes at 37°C. Following spinfection cultures were replenished with fresh media.

**3-D Agar-Based Colony Formation Assay**

Cells (10,000–20,000) were seeded in 0.35% soft agar (SeaPlaque GTG agarose; Lonza) cultures (1 mL of 0.8% base, 1 mL of 0.35% cell layer, 1 mL of liquid top layer in 6-well plates). Cells were allowed to rest overnight in 3-D before treatment with compound. For compound treatment, DMSO or ARS-853 was supplied into the top liquid media layer. For compound treatment, ARS-853 was supplied into the top liquid media layer. For shRNA experiments conducted in Fig. 3F, cells were seeded 48 hours after
transduction with indicated lentiviruses in media containing 1 μg/mL puromycin either in 2-D or 3-D agar-based formats. After 12 to 14 days, colonies were stained with 0.05% crystal violet, and foci formation was scored with colony counting software (NIH Image; particle analyzer).

**Cell Proliferation Assays**

For experiments conducted in 2-D adherent formats or 3-D ultra-low adherent formats, cells (800–1,200 per well) were seeded in standard tissue culture–treated 96-well format plates (Corning Costar #3903) or ultra-low attachment surface 96-well format plates (Corning Costar #3747). The day after plating, cells were treated with serial dilutions of indicated inhibitors. Five days later, cellular viability was assessed using CellTitre-glo (Promega) according to the manufacturer’s instructions. IC₅₀ calculations were performed in GraphPad Prism Version 6.0. For shRNA experiments conducted in Fig. 3F, cells using high-capacity Streptavidin agarose beads (30 and 0.1% NP-40, and the desthiobiotinylated peptides were enriched with 100 μL of 25 mmol/L Tris–HCl pH 7.4, 150 mmol/L NaCl, 0.1% NP-40; and water. Enriched peptides were eluted with 150 μL of 50% acetonitrile and 0.1% TFA, dried using a SpeedVac, and treated with compound for 4 hours at the indicated concentration.

**Proximity Ligation Assay**

Protein complexes were ligated together with a ligation reaction of 45 minutes at 37°C, and a rolling circle PCR amplification reaction for 100 minutes at 37°C (GFP version). Slides were subsequently air-dried for 1 hour at room temperature and mounted with ProLong Gold antifade (LifeTech) 20 minutes prior to acquisition. Cell-cycle analysis was monitored by the addition of FxCycle Violet stain (LifeTech) for 20 minutes prior to acquisition. Cell-cycle analysis was performed with a Miltenyi MACSQuant flow cytometer, and indicated populations were quantified using Flowjo software, V10.

**Cysteine Selectivity Profiling**

NCI-H358 cells (1 × 10⁶) were seeded overnight in 6-well plates and treated with compound for 4 hours at the indicated concentration. Cells were trypsinized and washed with PBS buffer. Cells were resuspended in a buffer containing 25 mmol/L Tris–HCl, pH 7.5, 150 mmol/L NaCl, 1% NP-40, 5% glycerol and protease inhibitor. Following probe sonication, cell extracts were treated with 100 μL of 50% acetonitrile and 0.1% TFA, dried using a Savant SPD100 centrifugal evaporator (Thermo Scientific), and stored at −20°C until LC/MS-MS analysis. A detailed description of the LC/MS-MS analysis procedure can be found in Supplementary Methods.

**NIH-3T3 KRAS Transformation**

3T3 cells (2 × 10⁴) transduced with indicated mutant KRAS lentiviruses were selected for 1 week with 1 μg/mL blasticidin and were subsequently plated in a top layer of 0.3% soft agar (SeaPlaque GTG agar; Lonza), cultured, and treated as described.

**Cell-Cycle Analysis by Flow Cytometry**

Cells plated in 6-well plates were treated for 72 hours as indicated. One hour prior to harvest, 2 μmol/L 5-ethyl-2′-deoxyuridine (EdU) was added to cultures to assess cycling cells. Cells were subsequently trypsinized, collected (including unattached cells), and washed with PBS. Cells were then fixed with 4% paraformaldehyde, permeabilized with saponin-based solution, and stained for EdU incorporation using the Click-iT EdU flow cytometry assay kit (LifeTech C10632) using the Alexa Fluor 488 azide per the provided instructions. DNA content was monitored by the addition of FixCycle Violet stain (LifeTech) 20 minutes prior to acquisition. Cell-cycle analysis was performed with a Miltenyi MACSQuant flow cytometer, and indicated populations were quantified using FlowJo software, V10.

**Chemical Synthesis of Compounds**

See supplementary information and Supplementary Fig. S1A–B.

**Disclosure of Potential Conflicts of Interest**

M.P. Patricelli reports receiving commercial research support from Janssen Biotech, Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. M.R. Janes has ownership interest (including patents) in Wellspring Biosciences LLC. L.-S. Li reports receiving commercial research support from Janssen Biotech, Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. U. Peters reports receiving commercial research support from Janssen Biotech, Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. J.M. Kucharski reports receiving commercial research support from Janssen Biotech, Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. T. Ely reports receiving commercial research support from Janssen Biotech Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. S.J. Firdaus reports receiving commercial research support from Janssen Biotech, Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. A. Babbar reports receiving commercial research support from Janssen Biotech Inc. and has ownership interest (including patents) in Wellspring Biosciences LLC. P. Ren has ownership interest (including patents) in Wellspring Biosciences LLC and is a consultant/advisory board member for the same. Y. Liu has ownership interest (including patents) in Wellspring Biosciences LLC and is a consultant/advisory board member for the same. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

**Conception and design:** M.P. Patricelli, M.R. Janes, U. Peters, Y. Liu

**Development of methodology:** M.P. Patricelli, M.R. Janes, R. Hansen, L.V. Kessler, J.H. Chen

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** R. Hansen, U. Peters, L.V. Kessler, J.M. Kucharski, T. Ely, S.J. Firdaus, A. Babbar

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** M.P. Patricelli, M.R. Janes, R. Hansen, U. Peters, J.M. Kucharski, J.H. Chen, A. Babbar, Y. Liu

**Writing, review, and/or revision of the manuscript:** M.P. Patricelli, M.R. Janes, J. Feng, T. Ely, P. Ren, Y. Liu

**DISCUSSION**
Targeting Inactive KRAS\textsubscript{G12C} Suppresses Oncogenic Signaling

RESEARCH ARTICLE

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-S. Li, L.V. Kessler, J.M. Kucharski, J. Feng

Study supervision: M.P. Patricelli, M.R. Janes

Other (designed and synthesized the molecules disclosed in this article): L.-S. Li

Other (designed and executed experiments): Y. Chen

Other (designed the molecules): P. Ren

Acknowledgments

The authors are grateful to Kevan Shokat for providing Compounds 11 and 12, discussion of the data, and comments on the manuscript, and to Frank McCormick for discussion. They acknowledge Shanghai Langtze Biomedical Technology for chemistry support on this program.

Atomic coordinates and structure factors for the ARS-853 crystal structure have been deposited to the Protein Data Bank (PDB: 5F2E).

Grant Support

This research is financially supported by Janssen Biotech, Inc. under a collaboration between Wellspring Biosciences LLC and Janssen Biotech. The costs of publication of this article were defrayed in part by

Other (designed and executed experiments): Y. Chen

M.P. Patricelli, M.R. Janes

J.M. Kucharski, J. Feng

L.-S. Li, L.V. Kessler, or organizing data, constructing databases): P. Ren

REFERENCES


Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Matthew P. Patricelli, Matthew R. Janes, Lian-Sheng Li, et al.